Networks of Excellence

This network is set to bring together key leaders to drive prenatal genomic medicine services by delivering more non-invasive prenatal testing. The network will also develop evidence to expand the eligibility for fetal genomic testing, as well as review clinical pathways. This network is co-led by the North Thames GMSA.

This NHS Genomic Network of Excellence will build on existing circulating biomarker testing projects, for example in non-small cell lung cancer, as it looks to expand the innovative test into a range of other tumour types. This network is co-led by the North Thames GMSA.

This NHS Genomic Network of Excellence will bring together experts to transform the understanding and management of patients with life threatening infectious disease, through the application of novel genomic technologies in pathogen detection and host immunity profiling. Professor Judith Brewer is a leading a work package within this Network, through the North Thames GMSA, to investigate how metagenomics can be used in the treatment of sterile site infections.

This NHS Genomic Network of Excellence will utilise expertise within the NHS Genomic Laboratory Hubs (GLHs) and NHS GMS Alliances to deliver new technologies for patients with or at risk of haematological malignancies, regardless of geographical location.

The focus of this NHS Genomic of Excellence is to help patients get a diagnosis faster; reduce genomic health inequalities; develop new testing approaches, especially for those patients with a suspected rare disease that remain undiagnosed using current genomic testing in the NHS GMS; increase the efficiency of analysis; and increase capacity for rare condition clinical trials.

This work will pilot approaches to improve the outcomes for individuals at risk of both inherited and acquired cardiovascular disease through precision diagnostics to tailor management in a well-established and phenotyped cohort of patients.

One approach to addressing adverse or ineffective medication reactions is to leverage knowledge of an individual’s genetic information to support medicines optimisation, better informing medicine selection and dosing, a concept known as pharmacogenetics. This NHS Genomic Network of Excellence will develop the rollout of pharmacogenomics and medicines optimisation in the NHS, including furthering the rollout in primary care.

The NHS Genomic Network of Excellence will build a national community in genomics and AI, create frameworks to support AI deployment for the benefit of NHS patients, including improved and accelerated diagnosis and personalised medicine.